期刊
BIOMEDICINES
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10123232
关键词
pluripotent stem cells; human induced pluripotent stem cells; kidney disease; autosomal dominant kidney disease; SARS-CoV-2 infection
资金
- Ministry of Science and Technology
- Kaohsiung Medical University
- Kaohsiung Medical University Hospital
- [MOST 111-2314-B-037-062]
- [KMU-TC111A02-6]
- [KMU-Q111005]
- [KMUH 110-011]
Human induced pluripotent stem cells (iPSCs) have opened up a wide range of opportunities for research and potential therapeutic uses since their discovery in 2007. This review examines the development of iPSC reprogramming and characterization technologies, provides an updated list of stem cell biobanks, and highlights important iPSC-based research on diseases such as autosomal dominant kidney disease and SARS-CoV-2 kidney involvement. The review also discusses challenges and future perspectives.
Human induced pluripotent stem cells (iPSCs), since their discovery in 2007, open a broad array of opportunities for research and potential therapeutic uses. The substantial progress in iPSC reprogramming, maintenance, differentiation, and characterization technologies since then has supported their applications from disease modeling and preclinical experimental platforms to the initiation of cell therapies. In this review, we started with a background introduction about stem cells and the discovery of iPSCs, examined the developing technologies in reprogramming and characterization, and provided the updated list of stem cell biobanks. We highlighted several important iPSC-based research including that on autosomal dominant kidney disease and SARS-CoV-2 kidney involvement and discussed challenges and future perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据